Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Insulet inks deal for Lilly’s Humalog concentrated insulin
Insulet said yesterday that it inked a deal with Eli Lilly to develop a version of its flagship OmniPod device that uses a concentrated insulin made by the pharma giant.
Lilly’s Humalog U200, which delivers 200 units of insulin per milliliter, is for patients who need higher doses of insuling to control their diabetes, Billerica, Mass.-based Insulet said. Read more
2. Advanced Inhalation Therapies scales back IPO terms to $10m
Advanced Inhalation Therapies yesterday scaled its pending initial public offering by more than ⅔ as it looks to raise funds for its drug delivery device, which is designed to treat severe respiratory infections and lung diseases using a high dose of nitric oxide.
When it registered for the IPO back in August 2015, Rehovot, Israel-based AIT set the high end of the offering at $36 million. Yesterday the company said it plans to float 675,000 shares at $15 apiece, for gross proceeds of $10.1 million. Read more
1. Supreme Court declines to review Medtronic win in InFuse lawsuit
The U.S. Supreme Court yesterday declined to review a Medtronic win in a lawsuit alleging off-label promotion of its controversial InFuse bone-growth protein.
Patricia Caplinger asked the high court last year to review an April decision by the U.S Court of Appeals for the 10th Circuit that her state-law tort claims are preempted by federal law. Caplinger had argued that her claims survived preemption because the device was used in a manner not approved by the FDA. Read more
